Survival: | 9.4 months |
Toxicity Grade: | 4 |
Treatments: | Chemotherapy |
Drugs: | Gemzar Platinol |
Country: | Netherlands |
City/State/Province: | Rotterdam |
Hospital: | University Hospital Rotterdam |
Journal: | Link |
Date: | 2/2002 |
Description: |
Patients: This Phase II trial involved 32 patients with malignant pleural mesothelioma. None of these patients had received prior chemotherapy. Treatment: The treatment consisted of two chemotherapy drugs, gemcitabine (gemzar) and cisplatin (platinol). Toxicity: Grade 4 toxicities included nausea and vomiting. Grade 3 toxicities included hematologic, nausea and vomiting, fatigue anorexia, diarrhea, neurotoxicity, cardiovascular. Results: The median survival from the start of treatment was 9.4 months. Support: This study was supported in part by Lilly BV. Lilly markets gemzar. Correspondence: JP van Meerbeeck, MD |